Entries by Jenny

Call for PBAC submissions to make Jakavi available for PV patients

Novartis is proposing to the Australian Pharmaceutical Benefits Advisory Committee that Jakavi (ruxolitinib) be made available on the PBS for patients with polycythemia vera (PV). Currently Jakavi is on the PBS for patients with myelofibrosis in certain circumstances. The use of Jakavi by Novartis is proposed for PV patients in certain circumstances – that is, […]

Share to:

New class of drugs being developed for treatment of polycythaemia vera

An update on the progress with these newly developed drugs is provided by Associate Professor David Ross, Consultant Haematologist at Royal Adelaide Hospital and Flinders Medical Centre, Adelaide ———————————————————————————— Treatment options for polycythaemia vera (PV) are limited at present. Hydroxyurea, a mild chemotherapy tablet, is the most widely used drug treatment in Australia, although the use […]

Share to:

Next Canberra MPN Coffee and Chat – 16 June at 10.30-12

We have a delightfully supportive and friendly group of MPN patients in the Canberra region so if you live in or around Canberra, please come and join us. There is always a great deal of news to share, experiences to recount, even sometimes blood test results to discuss! We are meeting in a lovely warm […]

Share to:

Video presentations available from the Joyce Niblack Memorial Conference on MPNs, 2019

You can now watch the video presentations from the 11th Joyce Niblack Memorial Conference on Myeloproliferative Neoplasms , 2-3 March 2019, Scottsdale, Arizona.  The powerpoints of the presentations are also available to read online. This biennial patient conference is organised by the MPN Education Foundation in the USA, and features presentations by many of the […]

Share to:

New study: Burden of Myeloproliferative Neoplasms in Australia revealed

New research led by Cancer Council Queensland and Curtin University has investigated the patterns and trends of myeloproliferative neoplasms (MPN) for the first time in Australia. The research, published in the American Journal of Hematology, explored the impact of MPN, which affects more than 5000 people in Australia currently, and found that the diagnosis and […]

Share to:

Patient Power interview with Nathalie Cook and Ken Young

Andrew and Esther Schorr from Patient Power in the USA have long been strong advocates for patient knowledge and empowerment. They recently visited Australia and New Zealand as part of their advocacy work. As Andrew has an MPN (myelofibrosis), he very much understands the issues and challenges involved in living with an MPN.  He and […]

Share to:

MPN Interferon Initiative Report

On the 30th November, Lara Chapman represented the MPN Alliance Australia as an invited guest, at the 2nd Annual ASH Meeting, hosted in San Diego by the MPN Research Foundation. The MPN AA would like to thank our partner organisation, MPN RF, for the invitation. We appreciate the opportunity to follow up on the progress […]

Share to:

Benefits of exercise for MPN patients

There has been some recent media attention about the value of exercise for cancer patients.  In May 2018, Associate Professor Prue Cormie, an accredited exercise physiologist explained that 26 cancer organisations were calling for exercise to be prescribed to all cancer patients as part of routine cancer care. See The Conversation – every cancer patient should be prescribed […]

Share to: